BAXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BAXTER INTERNATIONAL INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$24.99−0.29 (-1.15%)
Close on Oct 19, 2026
- Market cap
- $12.94B
- P/E (TTM)
- –
- Dividend yield
- 2.08%
BAXTER INTERNATIONAL INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Products & Therapies | $6.08B | $5.95B | $5.30B | $5.85B | $5.86B | $5.24B | $5.21B | $5.21B | $5.13B | $5.08B | $5.01B | $4.94B | 53.0% | +3.7% |
| Healthcare Systems & Technologies | $3.11B | $3.07B | $3.07B | $3.03B | $3.01B | $2.99B | $2.95B | $2.96B | $2.95B | $2.95B | $3.01B | $2.95B | 27.1% | +3.3% |
| Pharmaceuticals | – | $2.53B | $2.49B | $2.47B | $2.42B | $2.41B | $2.41B | $2.37B | $2.36B | $2.31B | $2.25B | $2.21B | – | – |
| Kidney Care | – | – | – | – | – | – | – | – | $4.49B | $4.49B | $4.45B | $4.46B | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Products & Therapies | $1.07B | $1.12B | $970.00M | $1.18B | $1.17B | $967.00M | $950.00M | $999.00M | $976.00M | $1.00B | $972.00M | $965.00M | -8.5% |
| Healthcare Systems & Technologies | $459.00M | $452.00M | $441.00M | $498.00M | $530.00M | $494.00M | $468.00M | $479.00M | $458.00M | $438.00M | $483.00M | $454.00M | -13.4% |
| Reportable Segment | -$268.00M | -$231.00M | -$308.00M | $180.00M | $209.00M | $42.00M | $14.00M | – | – | – | – | – | -228.2% |
| Other | – | – | – | – | – | – | – | $14.00M | $18.00M | $15.00M | $18.00M | $44.00M | – |
| Pharmaceuticals | – | $205.00M | $222.00M | $285.00M | $287.00M | $298.00M | $313.00M | $328.00M | $378.00M | $392.00M | $401.00M | $380.00M | – |
| Kidney Care | – | – | – | – | – | – | – | – | $430.00M | $402.00M | $300.00M | $309.00M | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $6.13B | $6.07B | $6.12B | $6.08B | $6.04B | $5.99B | $5.85B | $5.84B | $5.81B | $6.07B | $5.80B | $5.48B | 53.4% | +1.5% |
| International | $5.34B | $5.25B | $5.12B | $4.94B | $4.85B | $4.78B | $4.79B | $4.77B | $4.70B | $5.46B | $4.56B | $6.90B | 46.6% | +10.2% |
| Emerging markets | – | – | $1.39B | $1.35B | $1.34B | $1.34B | $1.35B | $1.36B | $1.37B | $1.86B | $1.34B | $2.82B | – | – |
| Rest of world | – | – | $3.73B | $3.60B | $3.51B | $3.44B | $3.44B | $3.41B | $3.34B | $3.60B | $3.22B | $4.08B | – | – |
From the segment and revenue-disaggregation notes of Baxter International's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.